Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 38 Colorectal Neoplasms 18 Small Cell Lung Carcinoma 8 Neoplasms 8 Stomach Neoplasms 7 Neoplasm Metastasis 5 Biliary Tract Neoplasms 5 Sarcoma, Ewing 4 Rhabdomyosarcoma 4 Recurrence 4 Osteosarcoma 4 Rectal Neoplasms 3 Ovarian Neoplasms 3 Cholangiocarcinoma 3 Triple Negative Breast Neoplasms 2 Solid Tumor 2 Neuroblastoma 2 Nasopharyngeal Carcinoma 2 Metastatic Pancreatic Adenocarcinoma 2 Head and Neck Neoplasms 2 Glioma 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Wilms Tumor 1 Weight Loss 1 Somatostatinoma 1 Solid Tumor Cancer 1 Small Cell Lung Cancer Extensive Stage 1

Interventions

Fulvestrant 6 Letrozole 4 Capecitabine 4 exemestane 3 dalpiciclib 3 Trastuzumab 3 Docetaxel 3 Anastrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Rogaratinib 1 Patient Reported Outcome Measures 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × irinotecan sucrosofate × Clear all

NCT03328884 2025-04-23

Phenomenal

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡